Population-based screening of stage 0-I lung cancer is crucial to save lives. In this article, we describe the development of a method for the detection of a CYFRA 21-1-autoantibody complex and CYFRA 21-1 in plasma samples. The CIC/CYFRA 21-1 ratio allows the detection of stage I-IV lung cancer with 76.0% sensitivity and 87.5% specificity.